Display options
Cite
Southey MC, Teo ZL, Winship I. PALB2 and breast cancer: ready for clinical translation!. Appl Clin Genet. 2013;6:43-52doi: 10.2147/TACG.S34116.
Southey, M. C., Teo, Z. L., & Winship, I. (2013). PALB2 and breast cancer: ready for clinical translation!. The application of clinical genetics, 643-52. https://doi.org/10.2147/TACG.S34116
Southey, Melissa C, et al. "PALB2 and breast cancer: ready for clinical translation!." The application of clinical genetics vol. 6 (2013): 43-52. doi: https://doi.org/10.2147/TACG.S34116
Southey MC, Teo ZL, Winship I. PALB2 and breast cancer: ready for clinical translation!. Appl Clin Genet. 2013 Jul 19;6:43-52. doi: 10.2147/TACG.S34116. Print 2013. PMID: 23935381; PMCID: PMC3735037.
Copy Download .nbib Format: NLM
Share it on

Appl Clin Genet. 2013 Jul 19;6:43-52. doi: 10.2147/TACG.S34116. Print 2013.

PALB2 and breast cancer: ready for clinical translation!.

The application of clinical genetics

Melissa C Southey, Zhi L Teo, Ingrid Winship

Affiliations

  1. Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Victoria, Australia.

PMID: 23935381 PMCID: PMC3735037 DOI: 10.2147/TACG.S34116

Abstract

For almost two decades, breast cancer clinical genetics has operated in an environment where a heritable cause of breast cancer susceptibility is identified in the vast minority of women seeking advice about their personal and/or family history of breast and/or ovarian cancer. A new wave of genetic information is upon us that promises to provide an explanation for the greater proportion of current missing heritability of breast cancer. Whilst researchers refine bioinformatic and analytic methodology necessary to interpret the new genetic data, attention needs to be paid to defining appropriate and coordinated pathways for the translation of this information so that it can be applied in clinical genetic services for the benefit of the majority of women who currently have no explanation for their breast cancer susceptibility. The search for additional breast cancer susceptibility genes remains a very active area of research. Exhausting the power of linkage studies that identified BRCA1 and BRCA2, the research community moved to candidate gene studies that led to the identification of ATM, BRIP1, CHEK2, and PALB2 as so-called "moderate-risk" breast cancer susceptibility genes. Mutations in these genes are rare and although early reports suggested that, on average, they are associated with moderate risks of breast cancer; population-based studies have demonstrated that at least some mutations in these genes are associated with breast cancer risks that are comparable to the average risk associated with BRCA2 mutations. The search for additional breast cancer susceptibility genes has now moved onto research platforms applying massively parallel sequencing capable of sequencing whole human exomes and genomes in single instrument runs. These programs are identifying a large number of additional putative breast cancer susceptibility genes, many of which are currently undergoing validation. It is highly anticipated that the remaining missing heritability of breast cancer will be due to mutations in many different genes, each explaining a small proportion of the currently unexplained heritable breast cancer susceptibility. The characterization of PALB2 as a breast cancer susceptibility gene and subsequent research that has refined our understanding of the prevalence and penetrance of heritable mutations in PALB2 offers a precious opportunity to use the data as a model and develop modes of translation that would be appropriate for the anticipated volume of imminent new information.

Keywords: PALB2; breast cancer risk; clinical genetics; translation

References

  1. Blood. 2004 Apr 1;103(7):2554-9 - PubMed
  2. Nature. 2007 Mar 15;446(7133):316-9 - PubMed
  3. Science. 2009 Apr 10;324(5924):217 - PubMed
  4. J Biol Chem. 2009 Jul 3;284(27):18302-10 - PubMed
  5. BMC Med Genet. 2010 Feb 02;11:20 - PubMed
  6. Fam Cancer. 2010 Jun;9(2):181-5 - PubMed
  7. Genome Res. 2012 Feb;22(2):340-5 - PubMed
  8. Clin Cancer Res. 2008 Jul 15;14(14):4667-71 - PubMed
  9. Eur J Hum Genet. 2012 May;20(5):577-9 - PubMed
  10. Breast Cancer Res. 2013 Feb 28;15(1):R17 - PubMed
  11. J Cell Sci. 2010 Apr 1;123(Pt 7):1124-30 - PubMed
  12. Br J Cancer. 2011 Mar 15;104(6):903-9 - PubMed
  13. Nature. 2013 Jan 17;493(7432):406-10 - PubMed
  14. Breast Cancer Res Treat. 2011 Apr;126(3):771-8 - PubMed
  15. Fam Cancer. 2011 Jun;10(2):225-31 - PubMed
  16. Breast Cancer Res. 2004;6(3):R199-214 - PubMed
  17. Nat Genet. 1996 May;13(1):123-5 - PubMed
  18. Mol Cell. 2006 Jun 23;22(6):719-729 - PubMed
  19. Am J Hum Genet. 2012 Apr 6;90(4):734-9 - PubMed
  20. Nat Genet. 2007 Feb;39(2):159-61 - PubMed
  21. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6788-93 - PubMed
  22. J Med Genet. 2007 Jan;44(1):1-9 - PubMed
  23. Gastroenterology. 2009 Sep;137(3):1183-6 - PubMed
  24. Fam Cancer. 2012 Mar;11(1):41-7 - PubMed
  25. Cancer Res. 2011 Mar 15;71(6):2222-9 - PubMed
  26. Prostate. 2008 May 1;68(6):675-8 - PubMed
  27. Breast Cancer Res Treat. 2009 Feb;113(3):545-51 - PubMed
  28. J Negat Results Biomed. 2008 Jul 17;7:5 - PubMed
  29. Mol Cell Biol. 2012 Apr;32(8):1506-17 - PubMed
  30. J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45 - PubMed
  31. Nat Struct Mol Biol. 2010 Oct;17(10):1255-9 - PubMed
  32. Nat Struct Mol Biol. 2010 Oct;17(10):1260-2 - PubMed
  33. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60 - PubMed
  34. Nat Genet. 1996 May;13(1):117-9 - PubMed
  35. Curr Biol. 2009 Mar 24;19(6):524-9 - PubMed
  36. Breast Cancer Res Treat. 2009 Apr;114(3):457-62 - PubMed
  37. Breast Cancer Res. 2012 Aug 28;14(4):R122 - PubMed
  38. Genes Chromosomes Cancer. 2013 May;52(5):480-94 - PubMed
  39. Nature. 1995 Dec 21-28;378(6559):789-92 - PubMed
  40. Cancer Res. 2010 Oct 1;70(19):7353-9 - PubMed
  41. Breast Cancer Res Treat. 2010 May;121(1):253-5 - PubMed
  42. Nat Genet. 2007 Feb;39(2):162-4 - PubMed
  43. Clin Genet. 2010 Nov;78(5):490-4 - PubMed
  44. J Clin Oncol. 2006 Feb 1;24(4):707-15 - PubMed
  45. J Clin Oncol. 2002 May 1;20(9):2310-8 - PubMed
  46. Clin Genet. 2009 Nov;76(5):421-6 - PubMed
  47. Breast Cancer Res Treat. 2011 Jun;127(2):357-62 - PubMed
  48. Hum Mutat. 2012 Apr;33(4):674-80 - PubMed
  49. Breast Cancer Res. 2007;9(6):R83 - PubMed
  50. Nat Genet. 2007 Feb;39(2):165-7 - PubMed
  51. Breast Cancer Res Treat. 2011 Apr;126(2):545-50 - PubMed
  52. Mol Cancer Ther. 2011 Jan;10(1):3-8 - PubMed
  53. Gene. 2001 Mar 21;266(1-2):111-21 - PubMed
  54. EMBO Rep. 2009 Sep;10(9):990-6 - PubMed
  55. Breast Cancer Res Treat. 2011 Apr;126(3):825-8 - PubMed
  56. Breast Cancer Res. 2010;12(6):R109 - PubMed
  57. EMBO Rep. 2012 Feb 01;13(2):135-41 - PubMed
  58. Clin Cancer Res. 2009 May 1;15(9):3214-22 - PubMed
  59. Fam Cancer. 2010 Dec;9(4):531-6 - PubMed
  60. Breast Cancer Res Treat. 2011 Feb;126(1):227-30 - PubMed
  61. Breast Cancer Res Treat. 2011 Jun;127(3):853-9 - PubMed
  62. Nat Struct Mol Biol. 2010 Oct;17(10):1247-54 - PubMed
  63. Fam Cancer. 2009;8(4):347-53 - PubMed
  64. Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47 - PubMed
  65. Fam Cancer. 2013 Dec;12(4):587-95 - PubMed
  66. J Med Genet. 2011 Aug;48(8):523-5 - PubMed
  67. Am J Hum Genet. 2003 May;72(5):1117-30 - PubMed
  68. Cancer Res. 1999 Apr 15;59(8):2011-7 - PubMed
  69. J Biol Chem. 2009 Aug 7;284(32):21127-31 - PubMed

Publication Types